MetaTOC stay on top of your field, easily

Change in metabolic parameters and weight in response to risperidone monotherapy in young children with nonpsychotic disorders: a prospective open‐label study

Child and Adolescent Mental Health

Published online on

Abstract

Background This study investigates changes in metabolic parameters in prepubertal children after 14–16 weeks of treatment with low‐dose risperidone. Method Thirty‐one children (mean age 5.46 ± 1.98 years) were treated with risperidone (0.25–1 mg/day; 0.01–0.07 mg/kg/day). Patients were excluded if they were using any medication other than risperidone or were diagnosed with any medical problem in addition to a non‐psychotic disorder. Results Weight (Δ: 2.51 ± 1.94 kg), height (Δ: 0.03 ± 0.04 cm), BMI (Δ: 0.82 ± 1.4), BMI percentile (Δ: 9.72 ± 16.40), BMI z‐score (Δ: 0.33 ± 1.03), triglyceride (Δ: 1.50 ± 23.97 mg/dl), very low density lipoprotein (Δ: 2.99 ± 4.76 mg/dl), insulin (Δ: 3.07 ± 3.38 mIU/ml), and leptin (Δ: 3.02 ± 4.69 ng/ml) were significantly increased (p < .05). Conclusion The metabolic side effects of risperidone must be carefully monitored in prepubertal children.